patients who met the following criteria-hepatic tumor unresectable because of location or inadequate liver reserve, no metastases, HBsAg negative, no tumor larger than 5 cm in diameter, and no more than three tumors-were enrolled prospectively in a protocol employing preoperative chemoembolization t
Preoperative chemoembolization for hepatocellular carcinoma
โ Scribed by Dr. Mario Morino; Claudio Miglietta; Maurizio Grosso; Maurizio de Giuli; Henri Bismuth
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 252 KB
- Volume
- 53
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
โฆ Synopsis
In a group of 396 patients who had chemoembolization for hepatocellular carcinoma (HCC) between 1984 and 1991, 67 underwent surgery (segmentaryhbsegmentary resections: 3 1 ; or transplantation: 36). Morbidity was limited to hepatic insufficiency (seven), arterial thrombosis (two), vasculitis (five), cholecystitis (two), and hepatic abscess (one). Perioperative mortality was 5.5% for transplantation and 6.7% for resection.
Histological examination of resected specimens showed a total or subtotal tumor necrosis in 58% of the cases, and a necrosis beween 50% and 80% in another 18%. Data on recurrence and long-term survival are not significant if retrospectively compared with non-chemoembolized surgically treated patients.
Chemoembolization is known to be an effective palliative treatment of HCC. Its role in the preoperative setting is substained by a 58% of total or subtotal histological necrosis. A multicentric prospective trial to evaluate the role of preoperative chemoembolization for long-term survival and recurrence of HCC is advocated.
๐ SIMILAR VOLUMES
In our experience, the primary obstacle precluding the widespread use of orthotopic liver transplantation (OLT) for definitive therapy of hepatocellular carcinoma (HCC), even for early-stage disease, is preventing tumor recurrence. Chemoembolization is an attractive strategy to minimize tumor progre